Focusing PSA Testing on Detection of High-Risk Prostate Cancers by Incorporating Patient Preferences Into Decision Making.

The article discusses the U.S. Preventive Services Task Force's recommendation against prostate-specific antigen (PSA) testing in general population due to the effect of detection and treatment and complications from treatment. Topics discussed include results of randomized clinical trials (RCT) of PSA screening in Europe and the U.S., development of a risk assessment tool to predict outcomes and recommendations for future improvements in decision-making tools.